Role of PPARγ in the development of the central nervous system

Folia Pharmacologica Japonica

Volumn 122, Issue 4, 2003, Pages 301-308

  Wada, Koichiro ^a   Kamisaki, Yoshinori ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Central nervous system; Cerebral infarction; Mouse; Neural stem cell; PPAR

Indexed keywords

CELL NUCLEUS RECEPTOR; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADIPOCYTE; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BRAIN DEVELOPMENT; BRAIN INFARCTION; BRAIN NERVE CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL STRUCTURE; CELL TYPE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EMBRYO; FETUS; IMMUNOHISTOCHEMISTRY; INSULIN SENSITIVITY; MOUSE; NERVE CELL GROWTH; NERVE CELL NECROSIS; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STEM CELL; WILD TYPE;

EID: 0142056009     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.122.301     Document Type: Review

References (27)

1. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-812.
2. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell. 1996;87:377-389.
3. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999; 4:597-609.
4. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998;4:1058-1061.
5. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 1999;354:141-148.
6. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421-424.
7. Nakajima A, Wada K, Miki H, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology. 2001;120:460-469.
8. Wada K, Nakajima A, Blumberg RS. PPAR gamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med. 2001;7:329-331.
9. Shiojiri T, Wada K, Nakajima A, et al. PPARγ ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol. 2002; 448:231-238.
10. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology. 2003;124:361-367.
11. Temple S. The development of neural stem cells. Nature. 2001;414:112-117.
12. Reh TA. Neural stem cells: form and function. Nat Neurosci. 2002;5:392-394.
13. Song H-J, Stevens CF, Gage FH. Neural stem cells from adult hippocampus develop essential properties of functional CNS neurons. Nat Neurosci. 2002;5:438-445.
14. Rossi F, Cattaneo, E. Neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci. 2002;3:401-409.
15. Torii M, Matsuzaki F, Osumi N, et al. Transcription factors Mash-1 and Prox-1 delineate early steps in differentiation of neural stem cells in the developing central nervous system. Development. 1999;126:443-456.
16. Kaneko Y, Sakakibara S, Imai T, et al. Musashi 1: an evolutionally conserved marker for CNS progenitor cells including neural stem cells. Dev Neurosci. 2000;22:139-153.
17. Khandoudi N, Delerive P, Berrebi-Bertrand I, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes. 2002;51:1507-1514.
18. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126-3132.
19. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002;16:1027-1040.
20. Umemura K, Wada K, Uematsu T, Nakashima M. Evaluation of the combination of a tissue-type plasminogen activator, SUN 9216, and a thromboxan A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke. 1993;24:1077-1082.
21. Tontonoz P, Hu E, Spiegelman BM. Stimulation of Adipogenesis in fibroblasts by PPARgamma 2, a lipid-activated transcription factor. Cell. 1994;79: 1147-1156.
22. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor- alpha, - beta, and -gamma during rat embryonic development. Endocrinology. 1998;139:2748-2754.
23. Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol. 1999;10:564-570.
24. Gritti A, Parati EA, Cova L, et al. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. J Neurosci. 1996;16:1091-1100.
25. Kudo C, et al. Diclofenac inhibits proliferation and differentiation of neural stem cells. Biochem Pharmacol. 2003;66:289-295.
26. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest. 2000;106:459-465.
27. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPAR gamma) deficiency and PPAR gamma agonist improve insulin resistance. J Biol Chem. 2001;276: 41245-41254.